[go: up one dir, main page]

DK0658198T3 - Multicistroniske ekspressionsenheder samt deres anvendelse - Google Patents

Multicistroniske ekspressionsenheder samt deres anvendelse

Info

Publication number
DK0658198T3
DK0658198T3 DK93919176T DK93919176T DK0658198T3 DK 0658198 T3 DK0658198 T3 DK 0658198T3 DK 93919176 T DK93919176 T DK 93919176T DK 93919176 T DK93919176 T DK 93919176T DK 0658198 T3 DK0658198 T3 DK 0658198T3
Authority
DK
Denmark
Prior art keywords
well
expression units
multicistronic expression
multicistronic
units
Prior art date
Application number
DK93919176T
Other languages
English (en)
Inventor
Wilhelm Dirks
Manfred Wirth
Hansjoerg Hauser
Wolfram Eichner
Volker Achterberg
Albrecht Dirschner
Wolfgang Meyer-Ingold
Heiko Mielke
Original Assignee
Beiersdorf Ag
Biotechnolog Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag, Biotechnolog Forschung Gmbh filed Critical Beiersdorf Ag
Application granted granted Critical
Publication of DK0658198T3 publication Critical patent/DK0658198T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
    • B29C48/50—Details of extruders
    • B29C48/76—Venting, drying means; Degassing means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/07—Flat, e.g. panels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK93919176T 1992-08-27 1993-08-26 Multicistroniske ekspressionsenheder samt deres anvendelse DK0658198T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4228458A DE4228458A1 (de) 1992-08-27 1992-08-27 Multicistronische Expressionseinheiten und deren Verwendung
PCT/EP1993/002294 WO1994005785A1 (de) 1992-08-27 1993-08-26 Multicistronische expressionseinheiten und deren verwendung

Publications (1)

Publication Number Publication Date
DK0658198T3 true DK0658198T3 (da) 1999-09-13

Family

ID=6466528

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93919176T DK0658198T3 (da) 1992-08-27 1993-08-26 Multicistroniske ekspressionsenheder samt deres anvendelse

Country Status (8)

Country Link
US (1) US6060273A (da)
EP (1) EP0658198B1 (da)
JP (1) JP3515110B2 (da)
AU (1) AU4953793A (da)
DE (2) DE4228458A1 (da)
DK (1) DK0658198T3 (da)
ES (1) ES2127831T3 (da)
WO (1) WO1994005785A1 (da)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939391A (en) * 1993-03-31 1999-08-17 Pro-Neuron, Inc. Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
US6610654B2 (en) 1993-03-31 2003-08-26 Wellstat Therapeutics Corporation Inhibitor of stem cell proliferation and uses thereof
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
DE19542051C2 (de) 1995-11-10 2000-03-23 Asta Medica Ag Gentechnisch veränderte tumorigene Zellinien und Verwendung derselben für die Testung von Antitumor-Wirkstoffen
WO1997018470A1 (en) 1995-11-16 1997-05-22 Matsushita Electric Industrial Co., Ltd. Method and apparatus for urinalysis, method of measuring optical rotation and polarimeter
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
EP0956301A2 (en) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 gene expression and delivery systems and uses
FR2762615B1 (fr) * 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6689879B2 (en) 1998-12-31 2004-02-10 Chiron Corporation Modified HIV Env polypeptides
EP2206785A1 (en) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
CA2358385C (en) * 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6610508B1 (en) 1999-03-08 2003-08-26 Anadys Pharmaceuticals, Inc. Translation driver system and methods for use thereof
AU2001231171B2 (en) * 2000-01-28 2007-01-04 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
CA2405363A1 (en) * 2000-04-28 2001-11-08 Ctl Immunotherapies Corp. Epitope synchronization in antigen presenting cells
JP2001299361A (ja) * 2000-04-28 2001-10-30 Oriental Yeast Co Ltd 溶液安定性の組換えヒトクレアチンキナーゼヘテロダイマー
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
JP2004500890A (ja) * 2000-06-19 2004-01-15 ジーティーシー　バイオセラピューティックス　インコーポレイテッド 遺伝子導入によって作成された血小板由来増殖因子
JP4510242B2 (ja) * 2000-07-11 2010-07-21 キヤノン株式会社 薄膜形成方法
AU2002327164A1 (en) * 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EA007388B1 (ru) * 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Модифицированные антитела и способы применения
EP2412242A3 (en) * 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
ITMI20012110A1 (it) * 2001-10-12 2003-04-12 Keryos Spa Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
AU2002337892A1 (en) * 2001-10-18 2003-04-28 Aventis Pharmaceuticals Inc. Vectors for expressing multiple transgenes
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
AU2002364956C1 (en) * 2001-11-16 2009-05-28 Biogen Idec Inc. Polycistronic expression of antibodies
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
AU2002366974A1 (en) * 2001-12-27 2003-07-30 Gbf-Gesellschaft Fur Biotechnologische Forschung Gmbh Methods of inducing or enhancing connective tissue repair
DK2348119T3 (da) * 2002-02-01 2017-08-21 Oxford Biomedica (Uk) Ltd Polycistronisk lentiviral vektor
US9738907B2 (en) 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
WO2003106684A2 (en) * 2002-06-14 2003-12-24 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
ATE354645T1 (de) * 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
EP1736546A4 (en) * 2004-03-23 2008-03-05 Eisai R&D Man Co Ltd METHOD FOR MEASURING TRANSCRIPTION ACTIVITY, METHOD FOR MEASURING CELL QUANTITY, AND TUMOR VOLUME MEASURING METHOD USING NON-HUMAN ANIMAL MODEL
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
NZ553700A (en) * 2004-11-08 2010-09-30 Chromagenics Bv Selection of host cells expressing protein at high levels using a selectable marker with a non-optimal start codon
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20100136616A1 (en) * 2004-11-08 2010-06-03 Chromagenics B.V. Selection of Host Cells Expressing Protein at High Levels
EP1885893A4 (en) * 2005-05-31 2010-12-08 Univ Rochester METHOD FOR DETERMINING THE IMMUNE GAINING OF VIRUS INFECTIVITY WITH FC RECEPTOR-TRANSFECTED CELL LINES
SG164383A1 (en) 2005-07-21 2010-09-29 Abbott Lab Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
CN101743306A (zh) 2007-03-23 2010-06-16 威斯康星校友研究基金会 体细胞重编程
RU2499599C2 (ru) 2007-09-28 2013-11-27 Интрексон Корпорейшн Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение
WO2009149233A1 (en) 2008-06-04 2009-12-10 Stem Cell Products, Inc. Methods for the production of ips cells using non-viral approach
CN107988261A (zh) 2008-08-12 2018-05-04 细胞动力国际有限公司 产生ips细胞的方法
CA2739902A1 (en) 2008-10-08 2010-04-15 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
EP2493923A1 (en) * 2009-10-30 2012-09-05 Abbott Laboratories Sorf constructs and multiple gene expression
DK2640743T3 (da) 2010-11-16 2017-01-23 Excelimmune Inc Fremgangsmåder til fremstilling af rekombinante proteiner
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
JP6279466B2 (ja) 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
MA45779A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Polypeptides immunomdulateurs et compositions et procédés associés
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
CN110494565A (zh) 2016-12-02 2019-11-22 朱诺治疗学股份有限公司 工程化b细胞及相关组合物和方法
JP2019536461A (ja) 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための操作細胞の産生
WO2018134691A2 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
DE102017103383A1 (de) 2017-02-20 2018-08-23 aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
US20230190796A1 (en) 2017-04-07 2023-06-22 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US11740231B2 (en) 2017-06-02 2023-08-29 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
MX2020000900A (es) 2017-07-29 2021-01-08 Juno Therapeutics Inc Reactivos para expandir celulas que expresan receptores recombinantes.
WO2019032675A1 (en) * 2017-08-08 2019-02-14 Sangamo Therapeutics, Inc. CELL TARGETING MEDIATED BY A CHIMERIC ANTIGEN RECEPTOR
AU2018313952B2 (en) 2017-08-09 2025-07-10 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
WO2019051335A1 (en) 2017-09-07 2019-03-14 Juno Therapeutics, Inc. METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
KR20200104284A (ko) 2017-10-03 2020-09-03 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
CN109837293A (zh) * 2017-11-24 2019-06-04 康码（上海）生物科技有限公司 一种能够增强蛋白质合成效率的串联dna元件
BR112020011144A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc formulação de meio livre de soro para o cultivo de células e métodos de uso da mesma
KR20250136416A (ko) 2017-12-08 2025-09-16 주노 쎄러퓨티크스 인코퍼레이티드 조작된 t 세포의 조성물의 제조방법
BR112020011223A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc marcadores fenotípicos para terapia celular e mé-todos relacionados
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
CN112585277A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
AU2019247200A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112584902A (zh) 2018-05-03 2021-03-30 朱诺治疗学股份有限公司 嵌合抗原受体（car）t细胞疗法和激酶抑制剂的组合疗法
WO2020033916A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
JP7504891B2 (ja) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド 操作された細胞組成物のマススペクトロメトリー分析のための方法
AU2019370705B2 (en) 2018-10-31 2026-01-22 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
CN113614108A (zh) 2018-11-01 2021-11-05 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
ES2968737T3 (es) 2018-11-06 2024-05-13 Juno Therapeutics Inc Proceso para producir células T manipuladas genéticamente
KR20210122272A (ko) 2019-01-29 2021-10-08 주노 쎄러퓨티크스 인코퍼레이티드 수용체 티로신 키나제 유사 고아 수용체 1(ror1)에 특이적인 항체 및 키메라 항원 수용체
CN114007640A (zh) 2019-05-01 2022-02-01 朱诺治疗学股份有限公司 从修饰的cd247基因座表达嵌合受体的细胞、相关多核苷酸和方法
CN114025788A (zh) 2019-05-01 2022-02-08 朱诺治疗学股份有限公司 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
CN112439056B (zh) * 2019-08-28 2022-05-31 中国农业科学院生物技术研究所 基于自组装铁蛋白纳米抗原颗粒及由其制备的o型口蹄疫疫苗和应用
US20220333132A1 (en) 2019-09-03 2022-10-20 Sana Blotechnology, Inc. Cd24-associated particles and related methods and uses thereof
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
AU2020379043A1 (en) 2019-11-07 2022-06-02 Juno Therapeutics, Inc. Combination of a T cell therapy and (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
WO2021151008A1 (en) 2020-01-24 2021-07-29 Juno Therapuetics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
CN115768443A (zh) 2020-02-12 2023-03-07 朱诺治疗学股份有限公司 Cd19定向嵌合抗原受体t细胞组合物和方法及其用途
MX2022009830A (es) 2020-02-12 2022-10-28 Juno Therapeutics Inc Composiciones de celulas t que expresan receptores de antigenos quimericos dirigidos a bcma y metodos y usos de las mismas.
EP4150057A2 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
AU2021308078A1 (en) 2020-07-17 2023-02-09 Children's Hospital Los Angeles Chimeric MyD88 receptors for redirecting immunosuppressive signaling and related compositions and methods
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
CA3210581A1 (en) 2021-03-22 2022-09-29 Neil HAIG Methods of determining potency of a therapeutic cell composition
WO2022212384A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019229A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
JP2024534772A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法用の遺伝子改変細胞
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
EP4384598A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
JP2024531827A (ja) 2021-08-13 2024-08-29 トリオヴァンス ホールディング リミテッド ライアビリティ カンパニー 代用皮膚組成物ならびにそれを製造および使用する方法
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023115049A1 (en) 2021-12-17 2023-06-22 Umoja Biopharma, Inc. Cytotoxic innate lymphoid cell and uses thereof
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
US20250333476A1 (en) 2022-02-17 2025-10-30 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
EP4482519A1 (en) 2022-02-22 2025-01-01 Juno Therapeutics, Inc. Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
IL316365A (en) 2022-04-20 2024-12-01 Bluesphere Bio Inc Allogeneic T cells for the treatment of hematological malignancies
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
KR20250022800A (ko) 2022-06-10 2025-02-17 우모자 바이오파마 인코포레이티드 조작된 줄기 세포 및 그의 용도
US20250382640A1 (en) 2022-06-29 2025-12-18 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
CN120051298A (zh) 2022-08-05 2025-05-27 朱诺治疗学股份有限公司 Gprc5d和bcma特异性嵌合抗原受体
KR20250084921A (ko) 2022-08-26 2025-06-11 주노 쎄러퓨티크스 인코퍼레이티드 델타-유사 리간드 3 (dll3)에 특이적인 항체 및 키메라 항원 수용체
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
IL322815A (en) 2023-02-28 2025-10-01 Juno Therapeutics Inc Cell therapy for the treatment of systemic autoimmune diseases
CN118638241A (zh) 2023-03-04 2024-09-13 四川三叶草生物制药有限公司 新型冠状病毒防护鼻喷剂及其制备和使用
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
AU2024280139A1 (en) 2023-05-30 2026-01-22 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine composition, method therefor and use thereof
WO2024251281A1 (zh) 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0259632B1 (en) * 1986-08-13 1995-12-13 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
WO1990001550A1 (en) * 1988-07-29 1990-02-22 Zymogenetics, Inc. High efficiency translation of polycistronic messages in eucaryotic cells
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
WO1993003143A1 (en) * 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen

Also Published As

Publication number Publication date
JP3515110B2 (ja) 2004-04-05
EP0658198A1 (de) 1995-06-21
ES2127831T3 (es) 1999-05-01
JPH08502644A (ja) 1996-03-26
DE59309352D1 (de) 1999-03-11
AU4953793A (en) 1994-03-29
WO1994005785A1 (de) 1994-03-17
DE4228458A1 (de) 1994-06-01
US6060273A (en) 2000-05-09
EP0658198B1 (de) 1999-01-27

Similar Documents

Publication Publication Date Title
DK0658198T3 (da) Multicistroniske ekspressionsenheder samt deres anvendelse
FI924198A7 (fi) Foerfarande foer igaongsaettning av en kortmeddelandesaendning i ett cellulaert radionaet, cellulaert radionaet samt abonnentregister i ett cellulaert radionaet
DE68924958D1 (de) Zeitweilige Schutzüberzugsmassen.
FI933274L (fi) Tvaerbundna, kvaevehaltiga vinylkopolymerer, foerfarande foer framstaellning av dessa samt anvaendning av dessa
DK0609734T3 (da) Substituerede triazolinoner samt deres anvendelse som herbicider
BR9307218A (pt) Primer
FI934149L (fi) Avlaegsnande av foeroreningar samt foerbaettring av minoritetsladdningsbaerarens livstid i kisel
FI943200A0 (fi) Foerfarande foer utnyttjande av avfallsvaermeenenergi i kraftverk
FI931414L (fi) Imidazolderivat, foerfarande foer deras framstaellning samt deras anvaendning i terapi
FI932094A0 (fi) Kylningsapparat i kranens vaexel
FI932720L (fi) Barriaerfilm samt foerfarande foer framstaellning daerav
FI932732A0 (fi) Rotorkonstruktion i en tvaolindningselektricitetsmaskin
DE69300957D1 (de) Kathodischer Korrosionsschutz.
FI932264A0 (fi) Gapformare i en pappersmaskin
FI930522A0 (fi) Kaasunkeräysyksikkö
FI930927A0 (fi) Banformningsparti i en pappersmaskin
FIU950356U0 (fi) Anordning foer oekning av oeppningstrycket i oevertrycksventilrna i en defekt aonggenerator
FI925685A0 (fi) Foerfarande i foerbraenningsmotorprocess
KR950009117U (ko) 추락방지용 안정장치
FI930419A0 (fi) Foerfarande foer kompensering av maetfel i en lutningsindikator
FI935289A0 (fi) Foerfarande foer justering av slingfiltret i en mottagare samt mottagare
FI934119A0 (fi) Foerfarande foer styrning av tvaettning av enheter i en automatisk tvaettlinje samt automatisk tvaettanordning
FI934066A0 (fi) Stabilointijyrsin
FI930662A0 (fi) Foerfarande foer aostadkommande av ett luftuppvaermningssystem i rumsutrymmen samt anordningar foer detta
FI894597L (fi) Staenkskydd.